Reporte zur Charge FU5682

Symptomtext

Really bad hives; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 11Jan2022 14:00 (Batch/Lot number: unknown) at the age of 34 years as dose 1, single for covid-19 immunisation; influenza vaccine (INFLUENZA), administered in arm right, administration date 11Jan2022 (Batch/Lot number: unknown) as dose 1, single; tetanus vaccine (TETANUS VACCINE), administered in arm right, administration date 11Jan2022 (Batch/Lot number: unknown) as dose 1, single. Relevant medical history included: "Asthma" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies:CEPHALOSPORINS" (unspecified if ongoing). Concomitant medication(s) included: LAMICTAL; MELATONIN; HYDROXYZINE. Past drug history included: Topamax, reaction(s): "Known allergies: Topamax"; Morphine, reaction(s): "Known allergies: Morphine"; Meloxicam, reaction(s): "Known allergies: Meloxicam"; Trazodone, reaction(s): "Known allergies: Trazodone". The following information was reported: URTICARIA (non-serious) with onset 17Jan2022 12:00, outcome "not recovered", described as "Really bad hives". The event "really bad hives" was evaluated at the physician office visit. Therapeutic measures were not taken as a result of urticaria. Additional information: Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient received Lamictal, melatonin, hydroxyzine and one a day vitamin within 2 weeks of vaccination. Patient stated that she got the shot and didn't have any side effects or reactions to it that day, but a week later, patient had really bad hives. Patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient was not tested for COVID-19. Reporter classified case as non-serious. The lot number for bnt162b2 was not provided and will be requested during follow up.